ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ACET Adicet Bio Inc

1.85
-0.25 (-11.90%)
Apr 24 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 1,478,484
Bid Price 1.86
Ask Price 1.89
News -
Day High 2.08

Low
1.10

52 Week Range

High
7.50

Day Low 1.865
Company Name Stock Ticker Symbol Market Type
Adicet Bio Inc ACET NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.25 -11.90% 1.85 19:55:19
Open Price Low Price High Price Close Price Prev Close
2.07 1.865 2.08 1.875 2.10
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
5,533 1,478,484 $ 1.97 $ 2,917,685 - 1.10 - 7.50
Last Trade Time Type Quantity Stock Price Currency
19:50:17 88 $ 1.86 USD

Adicet Bio Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
98.42M 43.16M - 0 -142.66M -3.31 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Adicet Bio News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No ACET Message Board. Create One! See More Posts on ACET Message Board See More Message Board Posts

Historical ACET Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week2.222.351.8652.08774,713-0.37-16.67%
1 Month2.262.431.8652.21626,272-0.41-18.14%
3 Months2.873.621.8652.501,305,424-1.02-35.54%
6 Months1.393.771.102.471,126,5990.4633.09%
1 Year6.197.501.102.66893,834-4.34-70.11%
3 Years14.4221.871.108.22649,778-12.57-87.17%
5 Years14.9821.871.108.43562,024-13.13-87.65%

Adicet Bio Description

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. The company is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients.

Your Recent History

Delayed Upgrade Clock